Non-alcoholic Steatohepatitis (NASH) is emerging as a leading cause of cirrhosis worldwide. Weight reduction through lifestyle modification is accepted first line treatment for these patients. Histological improvement in highrisk patient is the primary target of pharmacotherapy in NASH patients. Even though currently many drugs are available for these high-risk patients, none of them has been approved USA Food and Drug Administration (FDA) until now. Among these, vitamin E and pioglitazone has been approved by AASLD (American Association for the Study of Liver Diseases) in selected group of patients. There are more than a dozen drug targeting different pathways in NASH patient currently in phase 2 and 3 trails. Here we briefly review the currently available drugs and future of pharmacotherapy in NASH patients.
"Pharmacotherapy for Non-alcoholic Steatohepatitis - Current Status and Future Prospects,"
Manipal Journal of Medical Sciences: Vol. 6:
2, Article 5.
Available at: https://impressions.manipal.edu/mjms/vol6/iss2/5